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in 9 of the 11 countries studied, and for inpatients in 10
of the 11 countries studied. The weighted average ex-
pected cost per patient for MDD treatment varied from
US $642 (Poland) to US $5,825 (US). The estimated bud-
getary impact to the primary payer for each 1% of utili-
zation of extended-release venlafaxine ranged from US
$61,640 (Switzerland) to US $1,565,900 (Germany) for
each 1 million population. 
CONCLUSIONS: Policy-makers should implement mea-
sures to increase the utilization of cost-effective antide-
pressant treatment such as extended-release venlafaxine.
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OBJECTIVE: To assess the relationship between illness
severity and costs of care in noninstitutionalized patients
with Alzheimer’s Disease in the United Kingdom.
METHODS: In this cross-sectional, multicenter analysis,
Alzheimer’s Disease patients cared for in the community
(128), their caregivers (128), and 56 matched controls
were recruited chronologically and interviewed once to
establish resource use over the previous 3 months. Pa-
tients were stratified into three severity groups according
to their cognitive function as assessed by their Mini Men-
tal State Exam score. Costs were calculated from the per-
spective of society as a whole.
RESULTS: Over the 3-month period, total mean cost per
control subject (£387) was minor compared with the
mean cost incurred by patients with mild (£6,616), mod-
erate (£10,250), and severe (£13,593) Alzheimer’s Dis-
ease. Indirect cost, mainly time spent by caregivers, was
the main cost component in all groups (68.6%), followed
by direct medical costs (24.7%).
CONCLUSION: The cost of care for an Alzheimer’s Dis-
ease patient is substantial and is directly related to the se-
verity of the patient’s illness.
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OBJECTIVE: To develop a health-related quality of life
questionnaire to measure the effects of treatment on the
quality of life of people with schizophrenia, the Schizo-
phrenia Quality of Life Scale (SQLS).
METHODS: A standardized state-of-the-art methodol-
ogy has been used for the development of the SQLS.
Items were generated from in-depth interviews with 20
patients and eight health professionals. From a list of 440
statements, a pilot questionnaire containing 80 items was
developed by a panel of experts. The pilot questionnaire
was tested on 20 patients, which resulted in some word-
ing changes. A sample of 161 patients completed the 80-
item questionnaire. A factor analysis using Varimax rota-
tion was then conducted. This identified 31 questions
tapping three factors: psychological, motivational, and
physical symptoms. The psychometric properties of the
SQLS were then assessed using the following methodol-
ogy. Sixty-five patients were given the SQLS to complete,
along with the following measures: the SF-36, the Hospi-
tal Anxiety and Depression Scale (HADS), and the Gen-
eral Health Questionnaire (GHQ-12). A clinical assess-
ment using the Clinical Global Impressions and the
Health of the Nation Outcome Scales (HONOS) was
made by a psychiatrist. A subset of the patients was asked
to complete the SQLS for a second time to assess the re-
producibility of the measure.
RESULTS: The validity and reliability of the scale are
good. 
CONCLUSIONS: The SQLS is now available for use, al-
though further studies of its psychometric properties are
ongoing.
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With the increase of QoL assessment in clinical trials, it is
necessary to have cross-culturally valid instruments to
make comparisons of health status outcomes and pool
data across countries. The IIEF is a 15-item instrument
designed in English to assess erectile dysfunction. Prior to
use in an international trial, it underwent cross-cultural
adaptation in 31 languages. This involved the recruitment
of a QoL specialist in each target country. Two indepen-
dent forward translations were produced by native speak-
ers, bilingual in English. These were reconciled and back-
translated into English. The translations were tested for
comprehension in a sample target population, compared
and internationally harmonized. The developer clarified
concepts underlying each item. Translation was difficult,
especially when selecting equivalent response categories
and appropriate equivalents of common English struc-
tures and expressions. The difficulty of the translation
and its acceptability depended on the comparability of
the original and the target language and culture. Because
English is flexible, it was possible to accept “Most of the
times (much more than half of the time)” as an answer to
the question: “How often have you felt sexual desire in
